Tags

Type your tag names separated by a space and hit enter

Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Arch Dermatol. 2007 Jun; 143(6):711-6.AD

Abstract

OBJECTIVE

To assess the type of severe skin reactions caused by valdecoxib treatment.

DESIGN

Case registry of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

SETTING

All hospitals in Germany that treat patients with severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

PATIENTS

Five case notifications of Stevens-Johnson syndrome after the use of valdecoxib were reevaluated following the withdrawal of valdecoxib on April 7, 2005.

RESULTS

A thorough review of all reported cases of severe skin reactions caused by valdecoxib revealed extensive erythematous, targetlike skin eruptions in addition to facial edema and dyspnea. Histologic changes, clinical pattern, and outcome demonstrated a distinct disease entity.

CONCLUSION

Valdecoxib induces severe skin reactions different from those of Stevens-Johnson syndrome and toxic epidermal necrolysis in clinical and histopathologic findings, course, and outcome.

Authors+Show Affiliations

Department of Dermatology, University of Jena, Erfurter Strasse 35, D-07743 Jena, Germany. mirjana.ziemer@derma.uni-jena.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17576936

Citation

Ziemer, Mirjana, et al. "Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis." Archives of Dermatology, vol. 143, no. 6, 2007, pp. 711-6.
Ziemer M, Wiesend CL, Vetter R, et al. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2007;143(6):711-6.
Ziemer, M., Wiesend, C. L., Vetter, R., Weiss, J., Blaschke, S., Norgauer, J., & Mockenhaupt, M. (2007). Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Archives of Dermatology, 143(6), 711-6.
Ziemer M, et al. Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Arch Dermatol. 2007;143(6):711-6. PubMed PMID: 17576936.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. AU - Ziemer,Mirjana, AU - Wiesend,Christiane L, AU - Vetter,Robert, AU - Weiss,Johannes, AU - Blaschke,Sabine, AU - Norgauer,Johannes, AU - Mockenhaupt,Maja, PY - 2007/6/20/pubmed PY - 2007/7/27/medline PY - 2007/6/20/entrez SP - 711 EP - 6 JF - Archives of dermatology JO - Arch Dermatol VL - 143 IS - 6 N2 - OBJECTIVE: To assess the type of severe skin reactions caused by valdecoxib treatment. DESIGN: Case registry of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. SETTING: All hospitals in Germany that treat patients with severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. PATIENTS: Five case notifications of Stevens-Johnson syndrome after the use of valdecoxib were reevaluated following the withdrawal of valdecoxib on April 7, 2005. RESULTS: A thorough review of all reported cases of severe skin reactions caused by valdecoxib revealed extensive erythematous, targetlike skin eruptions in addition to facial edema and dyspnea. Histologic changes, clinical pattern, and outcome demonstrated a distinct disease entity. CONCLUSION: Valdecoxib induces severe skin reactions different from those of Stevens-Johnson syndrome and toxic epidermal necrolysis in clinical and histopathologic findings, course, and outcome. SN - 0003-987X UR - https://www.unboundmedicine.com/medline/citation/17576936/Cutaneous_adverse_reactions_to_valdecoxib_distinct_from_Stevens_Johnson_syndrome_and_toxic_epidermal_necrolysis_ L2 - https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/archderm.143.6.711 DB - PRIME DP - Unbound Medicine ER -